Free tool
Healthcare stocks
We cover 214 companies in the Healthcare sector. The median market value in the group is $3.71B. Across the group, the median move over the past trading day is 0.00%. 74% of the 205 with a 200-day average trade above it. Price change over the past year runs from −23.5% to +208.8% across the middle 80 percent of the group, with a median of +25.8%. Across the group, 1 company currently carries a tier A volume signal.
Other lists in this group
Table
214 of 2,203 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| PODD | Insulet Corporation | $9.94B | Mid cap | −57.12% |
| PTGX | Protagonist Therapeutics, Inc. | $9.80B | Mid cap | +146.62% |
| NUVL | Nuvalent Inc | $9.79B | Mid cap | +62.83% |
| OSCR | Oscar Health, Inc. | $9.55B | Mid cap | +83.55% |
| KRK.WA | Krka, d. d. | $9.44B | Mid cap | +35.83% |
| TWST | Twist Bioscience Corporation | $9.41B | Mid cap | +451.89% |
| DEMANT.CO | Demant A/S | $9.39B | Mid cap | +16.89% |
| WDH1.DE | Demant A/S | $9.33B | Mid cap | −8.29% |
| PCVX | Vaxcyte, Inc. | $9.09B | Mid cap | +99.97% |
| IMVT | Immunovant, Inc. | $9.07B | Mid cap | +189.13% |
| QGEN | Qiagen N.V. | $9.01B | Mid cap | −9.65% |
| QIA.DE | Qiagen N.V. | $8.99B | Mid cap | −5.08% |
| HQY | HealthEquity, Inc. | $8.75B | Mid cap | +18.69% |
| 4151.T | Kyowa Kirin Co., Ltd. | $8.74B | Mid cap | +5.98% |
| BRKR | Bruker Corporation | $8.69B | Mid cap | +70.56% |
| ATR | AptarGroup, Inc. | $8.60B | Mid cap | −1.89% |
| 4523.T | Eisai Co., Ltd. | $8.53B | Mid cap | +9.77% |
| TGTX | TG Therapeutics, Inc. Common Stock | $8.42B | Mid cap | +92.61% |
| ALKS | Alkermes plc | $8.25B | Mid cap | +68.07% |
| SYRE | Spyre Therapeutics, Inc. | $8.13B | Mid cap | +446.12% |
| RYTM | Rhythm Pharmaceuticals, Inc. | $7.78B | Mid cap | +9.35% |
| 2413.T | M3, Inc. | $7.76B | Mid cap | −13.96% |
| CAI | Caris Life Sciences, Inc. | $7.58B | Mid cap | −29.83% |
| 6869.T | Sysmex Corporation | $7.42B | Mid cap | +7.21% |
| ALK-B.CO | ALK-Abelló A/S | $7.35B | Mid cap | +6.87% |
| SRRK | Scholar Rock Holding Corporation | $7.31B | Mid cap | +74.18% |
| HNGE | Hinge Health, Inc. | $7.25B | Mid cap | +56.66% |
| 4528.T | Ono Pharmaceutical Co., Ltd. | $7.24B | Mid cap | +54.22% |
| SHL.AX | Sonic Healthcare Limited | $7.13B | Mid cap | −12.74% |
| CHE | Chemed Corporation | $7.11B | Mid cap | +20.79% |
| PACS | PACS Group, Inc. | $7.03B | Mid cap | +274.28% |
| HIMS | Hims & Hers Health, Inc. | $6.96B | Mid cap | −32.22% |
| CGON | CG Oncology, Inc. | $6.95B | Mid cap | +196.15% |
| 0126Z0.KS | SAMSUNG EPIS HOLDINGS | $6.77B | Mid cap | +11.33% |
| ERAS | Erasca, Inc. | $6.70B | Mid cap | +1112.03% |
| 3391.T | Tsuruha Holdings Inc. | $6.66B | Mid cap | +4.03% |
| E2XE34.SA | Exelixis, Inc. | $6.61B | Mid cap | +23.92% |
| LNTH | Lantheus Holdings, Inc. | $6.58B | Mid cap | +77.38% |
| ORKA | Oruka Therapeutics, Inc. | $6.58B | Mid cap | +555.07% |
| RADL3.SA | Raia Drogasil S.A. | $6.56B | Mid cap | +7.42% |
| 3088.T | MatsukiyoCocokara & Co. | $6.47B | Mid cap | −12.29% |
| HLUN-B.CO | H. Lundbeck A/S | $6.47B | Mid cap | +6.85% |
| COH.AX | Cochlear Limited | $6.39B | Mid cap | −53.99% |
| COGT | Cogent Biosciences, Inc. | $6.39B | Mid cap | +196.85% |
| 7747.T | Asahi Intecc Co., Ltd. | $6.34B | Mid cap | +52.84% |
| BLTE | Belite Bio, Inc | $6.31B | Mid cap | +144.07% |
| LQDA | Liquidia Corporation | $6.31B | Mid cap | +154.86% |
| AMRX | Amneal Pharmaceuticals, Inc. | $6.27B | Mid cap | +92.20% |
| TVTX | Travere Therapeutics, Inc. | $6.24B | Mid cap | +284.86% |
| XENE | Xenon Pharmaceuticals Inc. | $6.18B | Mid cap | +64.11% |
| BLCO.TO | Bausch + Lomb Corporation | $6.18B | Mid cap | +19.34% |
| BLCO | Bausch + Lomb Corporation | $6.16B | Mid cap | +18.56% |
| DNTH | Dianthus Therapeutics, Inc. | $6.13B | Mid cap | +356.93% |
| STVN | Stevanato Group S.p.A. | $6.11B | Mid cap | −0.09% |
| PTCT | PTC Therapeutics, Inc. Common Stock | $6.07B | Mid cap | +46.02% |
| CTEC.L | Convatec Group PLC | $6.06B | Mid cap | −2.44% |
| KNSA | Kiniksa Pharmaceuticals International, plc | $6.05B | Mid cap | +133.47% |
| RDNT | RadNet, Inc. | $6.05B | Mid cap | +7.27% |
| T1FX34.SA | Teleflex Incorporated | $6.00B | Mid cap | +0.29% |
| SECT-B.ST | Sectra AB (publ) | $5.99B | Mid cap | −10.34% |
| MIRM | Mirum Pharmaceuticals, Inc. | $5.98B | Mid cap | +31.96% |
| DFTX | Definium Therapeutics, Inc. | $5.88B | Mid cap | +344.37% |
| TFX | Teleflex Incorporated | $5.88B | Mid cap | +8.06% |
| LGND | Ligand Pharmaceuticals Incorporated | $5.74B | Mid cap | +80.92% |
| CRSP | CRISPR Therapeutics AG | $5.73B | Mid cap | +10.65% |
| SHC | Sotera Health Company | $5.58B | Mid cap | +18.42% |
| MMED | MiniMed Group, Inc. | $5.48B | Mid cap | +5.41% |
| MMSI | Merit Medical Systems, Inc. | $5.44B | Mid cap | −0.28% |
| GRFS | Grifols, S.A. | $5.38B | Mid cap | −19.39% |
| ACAD | ACADIA Pharmaceuticals Inc. | $5.07B | Mid cap | +11.33% |
| 326030.KS | SK Biopharmaceuticals Co., Ltd. | $5.02B | Mid cap | −10.75% |
| DYN | Dyne Therapeutics, Inc. | $4.92B | Mid cap | +93.26% |
| EWTX | Edgewise Therapeutics, Inc. | $4.80B | Mid cap | +207.13% |
| 128940.KS | Hanmi Pharm. Co., Ltd. | $4.70B | Mid cap | +68.60% |
| LFST | LifeStance Health Group, Inc. | $4.69B | Mid cap | +121.31% |
| CELC | Celcuity Inc. | $4.65B | Mid cap | +90.31% |
| WAY | Waystar Holding Corp. | $4.63B | Mid cap | −34.97% |
| 000100.KS | Yuhan Corporation | $4.63B | Mid cap | −24.80% |
| HIK.L | Hikma Pharmaceuticals PLC | $4.56B | Mid cap | −8.60% |
| BLLN | BillionToOne, Inc. | $4.54B | Mid cap | −11.68% |
| ICUI | ICU Medical, Inc. | $4.49B | Mid cap | +41.83% |
| NVST | Envista Holdings Corporation | $4.47B | Mid cap | +30.89% |
| ELVN | Enliven Therapeutics, Inc. | $4.46B | Mid cap | +194.32% |
| CON | Concentra Group Holdings Parent, Inc. | $4.44B | Mid cap | +50.93% |
| OBCK.DE | Ottobock SE & Co. KGaA | $4.43B | Mid cap | −0.74% |
| DOCS | Doximity, Inc. | $4.41B | Mid cap | −63.61% |
| LIVN | LivaNova PLC | $4.41B | Mid cap | +41.56% |
| MANE | Veradermics, Incorporated | $4.29B | Mid cap | +172.32% |
| TNGX | Tango Therapeutics, Inc. | $4.29B | Mid cap | +269.13% |
| RLAY | Relay Therapeutics, Inc. | $4.26B | Mid cap | +445.10% |
| INDV | Indivior Pharmaceuticals, Inc. | $4.23B | Mid cap | +47.06% |
| 4506.T | Sumitomo Pharma Co., Ltd. | $4.18B | Mid cap | −2.62% |
| ADPT | Adaptive Biotechnologies Corporation | $4.18B | Mid cap | +101.70% |
| 1SXP.DE | SCHOTT Pharma AG & Co. KGaA | $4.14B | Mid cap | +3.26% |
| IRTC | iRhythm Holdings, Inc. | $4.06B | Mid cap | −29.83% |
| LEGN | Legend Biotech Corporation | $4.02B | Mid cap | −40.44% |
| VKTX | Viking Therapeutics, Inc. | $4.01B | Mid cap | +29.15% |
| DNLI | Denali Therapeutics Inc. | $3.98B | Mid cap | +57.50% |
| MCOV-B.ST | Medicover AB (publ) | $3.92B | Mid cap | −6.91% |
| RCUS | Arcus Biosciences, Inc. | $3.92B | Mid cap | +191.29% |
| BBZA.DE | BB Biotech AG | $3.87B | Mid cap | +7.22% |
| FIE.DE | Fielmann Group AG | $3.86B | Mid cap | −24.08% |
| 000105.KS | Yuhan Corporation | $3.84B | Mid cap | −31.22% |
| TLX.AX | Telix Pharmaceuticals Limited | $3.82B | Mid cap | +7.19% |
| CAMX.ST | Camurus AB (publ) | $3.80B | Mid cap | −15.56% |
| TLX | Telix Pharmaceuticals Limited | $3.77B | Mid cap | −8.02% |
| 4536.T | Santen Pharmaceutical Co., Ltd. | $3.72B | Mid cap | +20.92% |
| 7459.T | MediPal Holdings Corporation | $3.70B | Mid cap | +12.97% |
| IOVA | Iovance Biotherapeutics, Inc. | $3.66B | Mid cap | +233.88% |
| OPCH | Option Care Health, Inc. | $3.60B | Mid cap | −15.91% |
| VCYT | Veracyte, Inc. Common Stock | $3.56B | Mid cap | +54.81% |
| GPCR | Structure Therapeutics Inc. | $3.56B | Mid cap | +159.74% |
| GRAL | GRAIL, Inc. | $3.55B | Mid cap | +136.66% |
| QURE | uniQure N.V. | $3.53B | Mid cap | +223.49% |
| NHC | National HealthCare Corporation | $3.53B | Mid cap | +103.83% |
| ZEAL.CO | Zealand Pharma A/S | $3.39B | Mid cap | −25.81% |
| 22Z.DE | Zealand Pharma A/S | $3.36B | Mid cap | −29.60% |
| IMNM | Immunome, Inc. | $3.34B | Mid cap | +188.94% |
| AFX.DE | Carl Zeiss Meditec AG | $3.28B | Mid cap | −25.79% |
| NAMS | NewAmsterdam Pharma Company N.V. | $3.27B | Mid cap | +11.97% |
| 3349.T | COSMOS Pharmaceutical Corporation | $3.24B | Mid cap | −25.81% |
| MBX | MBX Biosciences, Inc. | $3.22B | Mid cap | +366.53% |
| BEAM | Beam Therapeutics Inc. | $3.21B | Mid cap | +79.06% |
| TMDX | TransMedics Group, Inc. | $3.19B | Mid cap | −21.43% |
| CLDX | Celldex Therapeutics, Inc. | $3.19B | Mid cap | +79.51% |
| IRON | Disc Medicine, Inc. | $3.17B | Mid cap | +37.90% |
| VIRP.PA | Virbac SA | $3.17B | Mid cap | −3.58% |
| WRBY | Warby Parker Inc. | $3.15B | Mid cap | −3.96% |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.12B | Mid cap | +60.64% |
| TARS | Tarsus Pharmaceuticals, Inc. | $3.10B | Mid cap | +22.19% |
| BIOA-B.ST | BioArctic AB (publ) | $3.10B | Mid cap | +10.37% |
| ALMS | Alumis Inc. | $3.06B | Mid cap | +380.08% |
| ASKER.ST | Asker Healthcare Group AB (publ) | $3.04B | Mid cap | −20.70% |
| HYPE3.SA | Hypera S.A. | $2.98B | Mid cap | −4.69% |
| BKD | Brookdale Senior Living Inc. | $2.91B | Mid cap | +55.61% |
| ALHC | Alignment Healthcare, Inc. | $2.88B | Mid cap | −13.88% |
| AMBU-B.CO | Ambu A/S | $2.87B | Mid cap | −25.78% |
| ACHC | Acadia Healthcare Company, Inc. | $2.85B | Mid cap | +37.81% |
| B72.DE | AtaiBeckley Inc. | $2.79B | Mid cap | +59.69% |
| SLS | SELLAS Life Sciences Group, Inc. | $2.77B | Mid cap | +615.10% |
| NRIX | Nurix Therapeutics, Inc. | $2.77B | Mid cap | +179.69% |
| VRDN | Viridian Therapeutics, Inc. | $2.75B | Mid cap | +30.71% |
| 9989.T | Sundrug Co.,Ltd. | $2.74B | Mid cap | −16.61% |
| ATAI | AtaiBeckley Inc. | $2.74B | Mid cap | +61.71% |
| RGC | Regencell Bioscience Holdings Limited | $2.72B | Mid cap | −61.38% |
| WGS | GeneDx Holdings Corp. | $2.69B | Mid cap | −30.11% |
| AXGN | AxoGen, Inc. Common Stock | $2.68B | Mid cap | +219.58% |
| VERA | Vera Therapeutics, Inc. | $2.65B | Mid cap | +67.21% |
| PGEN | Precigen, Inc. | $2.65B | Mid cap | +61.66% |
| EBO.AX | EBOS Group Limited | $2.64B | Mid cap | −37.11% |
| SUPN | Supernus Pharmaceuticals, Inc. | $2.61B | Mid cap | −0.42% |
| RARE | Ultragenyx Pharmaceutical Inc. | $2.61B | Mid cap | −12.10% |
| PHVS | Pharvaris N.V. | $2.60B | Mid cap | +55.59% |
| BHVN | Biohaven Ltd. | $2.56B | Mid cap | +8.65% |
| TRVI | Trevi Therapeutics, Inc. | $2.55B | Mid cap | +124.00% |
| 2784.T | Alfresa Holdings Corporation | $2.54B | Mid cap | +7.30% |
| NEOG | Neogen Corporation | $2.54B | Mid cap | +103.83% |
| RAPP | Rapport Therapeutics, Inc. | $2.52B | Mid cap | +250.70% |
| NKTR | Nektar Therapeutics | $2.52B | Mid cap | +151.95% |
| BCRX | BioCryst Pharmaceuticals, Inc. | $2.51B | Mid cap | +15.38% |
| CURA.TO | Curaleaf Holdings, Inc. | $2.51B | Mid cap | +197.74% |
| 3549.T | Kusuri No Aoki Holdings Co., Ltd. | $2.50B | Mid cap | +8.81% |
| KOD | Kodiak Sciences Inc. | $2.48B | Mid cap | +321.09% |
| PBH | Prestige Consumer Healthcare Inc. | $2.47B | Mid cap | −22.12% |
| NUVB | Nuvation Bio Inc. | $2.44B | Mid cap | +135.93% |
| BHC | Bausch Health Companies Inc. | $2.43B | Mid cap | −10.45% |
| BHC.TO | Bausch Health Companies Inc. | $2.43B | Mid cap | −9.88% |
| DRW3.DE | Drägerwerk AG & Co. KGaA | $2.42B | Mid cap | +72.02% |
| KLRA | Kailera Therapeutics, Inc. | $2.39B | Mid cap | −29.08% |
| OCUL | Ocular Therapeutix, Inc. | $2.37B | Mid cap | −12.58% |
| ALMR | Alamar Biosciences, Inc. | $2.36B | Mid cap | +54.91% |
| GRDN | Guardian Pharmacy Services, Inc. | $2.36B | Mid cap | +45.50% |
| 009420.KS | Hanall Biopharma Co., Ltd. | $2.36B | Mid cap | +116.42% |
| UFPT | UFP Technologies, Inc. | $2.36B | Mid cap | +41.94% |
| HRMY | Harmony Biosciences Holdings, Inc. | $2.31B | Mid cap | +4.23% |
| DMP.DE | Dermapharm Holding SE | $2.31B | Mid cap | +21.43% |
| BFLY | Butterfly Network, Inc. | $2.30B | Mid cap | +450.32% |
| COAG | Hemab Therapeutics Holdings, Inc. | $2.30B | Mid cap | +44.68% |
| MSB.AX | Mesoblast Limited | $2.30B | Mid cap | +12.84% |
| MLYS | Mineralys Therapeutics, Inc. | $2.28B | Mid cap | +70.22% |
| NBTX | Nanobiotix S.A. | $2.26B | Mid cap | +394.99% |
| CLOV | Clover Health Investments, Corp. | $2.26B | Mid cap | +57.99% |
| NANO.PA | Nanobiotix S.A. | $2.25B | Mid cap | +387.64% |
| ADUS | Addus HomeCare Corporation | $2.25B | Mid cap | +4.50% |
| URGN | UroGen Pharma Ltd. | $2.25B | Mid cap | +135.11% |
| MESO | Mesoblast Limited | $2.23B | Mid cap | +4.47% |
| PVLA | Palvella Therapeutics, Inc. | $2.22B | Mid cap | +173.39% |
| AUPH | Aurinia Pharmaceuticals Inc. | $2.20B | Mid cap | +36.58% |
| 008930.KS | Hanmi Science Co., Ltd. | $2.20B | Mid cap | +9.26% |
| 9987.T | Suzuken Co., Ltd. | $2.19B | Mid cap | −9.81% |
| GN.CO | GN Store Nord A/S | $2.19B | Mid cap | −16.23% |
| MD | Pediatrix Medical Group, Inc. | $2.19B | Mid cap | +56.87% |
| 302440.KS | SK bioscience Co.,Ltd. | $2.18B | Mid cap | −17.57% |
| XRAY | DENTSPLY SIRONA Inc. | $2.18B | Mid cap | −21.61% |
| EXE.TO | Extendicare Inc. | $2.18B | Mid cap | +146.56% |
| VCEL | Vericel Corporation | $2.17B | Mid cap | +18.25% |
| EKTA-B.ST | Elekta AB (publ) | $2.16B | Mid cap | +22.79% |
| ADMA | ADMA Biologics, Inc. | $2.16B | Mid cap | −44.17% |
| HCM.L | HUTCHMED (China) Limited | $2.16B | Mid cap | −17.57% |
| ZBIO | Zenas BioPharma, Inc. | $2.15B | Mid cap | +97.73% |
| ALIF-B.ST | AddLife AB (publ) | $2.15B | Mid cap | −4.16% |
| ESTA | Establishment Labs Holdings Inc. | $2.15B | Mid cap | +70.71% |
| CLOV34.SA | Clover Health Investments, Corp. | $2.15B | Mid cap | +45.23% |
| HCM | HUTCHMED (China) Limited | $2.15B | Mid cap | −17.45% |
| STOK | Stoke Therapeutics, Inc. | $2.14B | Mid cap | +71.45% |
| GNS.L | Genus plc | $2.12B | Mid cap | −10.24% |
| ZYME | Zymeworks Inc. | $2.10B | Mid cap | +96.28% |
| NVCR | NovoCure Limited | $2.08B | Mid cap | +50.21% |
| GENB | Generate Biomedicines, Inc. | $2.07B | Mid cap | +27.59% |
| PRGO | Perrigo Company plc | $2.05B | Mid cap | −36.05% |
| SEM | Select Medical Holdings Corp | $2.05B | Mid cap | +28.14% |
| AGIO | Agios Pharmaceuticals, Inc. Common Stock | $2.03B | Mid cap | −13.45% |
| CMPS | COMPASS Pathways plc | $2.02B | Mid cap | +209.53% |
| 6960.T | Fukuda Denshi Co., Ltd. | $2.01B | Mid cap | +80.63% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.